Glenmark Pharma Share Price in Focus; Launches Adapalene Gel Pump Packs

Written by: Team Angel OneUpdated on: 6 Oct 2026, 5:02 pm IST

Glenmark has launched new pump packs of Adapalene Gel 0.1% in the US, targeting a market with $45.8 million in annual sales.

Glenmark Pharmaceuticals has launched new pump-pack versions of Adapalene Gel USP, 0.1% through its US subsidiary Glenmark Therapeutics Inc, as per the exchange filing. The product is available in 15 g and 45 g pump packs.

The launch comes in the US market, where the Differin Gel 0.1% OTC market recorded annual sales of approximately $45.8 million in the 52 weeks ended September 5, 2026, according to Nielsen data cited by Glenmark.

Glenmark Adds New Pump-Pack Formats

The company has introduced the product in two pump sizes, 15 g and 45 g. The packs are listed for purchase through Amazon and Walmart.com.

Glenmark's Adapalene Gel USP, 0.1% can be compared with the active ingredient of Differin Gel 0.1%, according to the company's release.

$45.8 Million Market in Focus

The market data cited by Glenmark covers the brand as well as available therapeutic equivalents. Annual sales for the 52-week period ended September 5, 2026 stood at around $45.8 million.

This gives the latest launch a sizeable existing US market alongside Glenmark's expanding dermatology portfolio.

Management on New Format

Marc Kikuchi, President & Business Head, North America at Glenmark, said the pump pack offers consumers a more convenient and easy-to-use dispensing option.

He also said the launch strengthens the company's US dermatology portfolio and supports its focus on affordable healthcare solutions.

As of 06 October 2026, at 10:43 AM, Glenmark Pharmaceuticals Ltd share price was trading at ₹2,300.30 per share, reflecting a surge of 0.23% from the previous trading session.

Conclusion

Glenmark's latest US launch adds new pump-pack options to its Adapalene Gel portfolio, with the product entering a market that already has substantial annual sales.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Published on: Oct 6, 2026, 11:32 AM IST

Team Angel One

Team Angel One is a group of experienced financial writers that deliver insightful articles on the stock market, IPO, economy, personal finance, commodities and related categories.

Know More